Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives
- PMID: 7508411
- PMCID: PMC1374499
- DOI: 10.1136/gut.35.2.231
Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives
Abstract
The relationships between clinical activity, endoscopic severity, and biological parameters in Crohn's disease have not been thoroughly investigated and a link was therefore sought between these three elements. The following parameters were determined simultaneously in 121 consecutive patients with colonic or ileocolonic Crohn's disease: Crohn's disease activity index, Crohn's disease endoscopic index of severity, and serum albumin, alpha 2-globulin, alpha 1-antitrypsin, orosomucoid, C reactive protein, erythrocyte sedimentation rate, platelets, lymphocyte and polymorphonuclear cell counts, haematocrit, and faecal alpha 1-antitrypsin concentration. The distribution of these parameters was studied and transformation was used so that data matched the normal distribution closely. A weak but significant correlation (r = 0.32; p < 0.001) was found between clinical and endoscopic indices in the whole group of patients and this correlation seemed to be homogenous in various patient subgroups (clinically quiescent or active disease, pure colonic disease, untreated patients). Endoscopic or clinical indices were also found to be weakly linked with biological parameters (r < 0.50). Stepwise linear regression identified C reactive protein as predictive of the clinical index, and, successively, alpha 2-globulin, erythrocyte sedimentation rate, faecal alpha 1-antitrypsin, serum orosomucoid, and alpha 1-antitrypsin as predictive of the endoscopic index. Both predictions were poor--the biological variables accounting for only 22 and 44% respectively of the clinical and endoscopic index variations. In conclusion, Crohn's disease clinical activity seems to be virtually independent of the severity of the mucosal lesions and biological activity.
Similar articles
-
Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).Gut. 1989 Jul;30(7):983-9. doi: 10.1136/gut.30.7.983. Gut. 1989. PMID: 2668130 Free PMC article. Clinical Trial.
-
Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).Eur J Gastroenterol Hepatol. 1996 Mar;8(3):229-33. doi: 10.1097/00042737-199603000-00008. Eur J Gastroenterol Hepatol. 1996. PMID: 8724022 Clinical Trial.
-
Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.Gastroenterology. 1990 Apr;98(4):811-8. doi: 10.1016/0016-5085(90)90002-i. Gastroenterology. 1990. PMID: 2179031 Clinical Trial.
-
Colonoscopic findings in Crohn's disease--reproducible, but of questionable benefit.Can J Gastroenterol. 1996 Oct;10(6):405-12. doi: 10.1155/1996/353967. Can J Gastroenterol. 1996. PMID: 9193778 Review.
-
The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease.J Crohns Colitis. 2025 Feb 4;19(2):jjae122. doi: 10.1093/ecco-jcc/jjae122. J Crohns Colitis. 2025. PMID: 39207018 Review.
Cited by
-
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.J Crohns Colitis. 2024 Jun 3;18(6):818-827. doi: 10.1093/ecco-jcc/jjad206. J Crohns Colitis. 2024. PMID: 38069472 Free PMC article. Clinical Trial.
-
Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease.Antioxidants (Basel). 2019 Sep 1;8(9):351. doi: 10.3390/antiox8090351. Antioxidants (Basel). 2019. PMID: 31480545 Free PMC article.
-
Evaluation of new therapies for inflammatory bowel disease.Br J Clin Pharmacol. 2003 Oct;56(4):351-61. doi: 10.1046/j.1365-2125.2003.01965.x. Br J Clin Pharmacol. 2003. PMID: 12968979 Free PMC article. Review.
-
A Role for CXCR3 Ligands as Biomarkers of Post-Operative Crohn's Disease Recurrence.J Crohns Colitis. 2022 Jul 14;16(6):900-910. doi: 10.1093/ecco-jcc/jjab186. J Crohns Colitis. 2022. PMID: 34698823 Free PMC article.
-
Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?Intest Res. 2016 Jan;14(1):5-14. doi: 10.5217/ir.2016.14.1.5. Epub 2016 Jan 25. Intest Res. 2016. PMID: 26884729 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials